News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 14 stocks Jim Cramer recently shared insights on. Discussing the ...
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...
3don MSN
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1.0 to $80.0 for Hims & Hers Health over the last 3 months.
Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...
Zacks Investment Research on MSN19h
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerA downtrend has been apparent in Hims & Hers Health, Inc. (HIMS) lately with too much selling pressure. The stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback